Abstract: Novel TNF? antibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to treat TNF?-related diseases are also disclosed.

Abstract: DNA sequences that increase peptide chain expression when operably linked to a gene encoding the peptide chain and methods of generating a peptide chain expression host cell using the foregoing are disclosed. Peptide chain expression host cells are also disclosed.

Abstract: Methods for altering the cellular secretion rate of a protein, such as an antibody and the altered cells produced by the method are disclosed. The methods and altered cells are useful for producing high levels of proteins for therapeutic, diagnostic or research purposes.

Abstract: Isolated polynucleotides encoding Cynomolgus monkey prostate specific antigen and polypeptides obtainable from the polynucleotides and uses are disclosed.

Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.

Abstract: Tie2 receptor antagonist antibodies, their use in inhibiting angiogenesis and other uses are disclosed.

Abstract: Tie2 receptor agonist antibodies, their use in enhancing angiogenesis and other uses are disclosed.

Abstract: Oligodeoxynucleotides are provided which are targeted to the nucleic acids encoding receptor negative regulatory domains. In a preferred embodiment, the oligodeoxynucleotides are targeted to the EPOR negative regulatory domain. Methods of enhancing cell growth through use of the oligodeoxynucleotides are also provided.

Abstract: The present invention provides a protein fragment of the ob protein, being an active site of the protein. The active site is suitably provided by the ob protein when it is in the form of a four helix bundle structure, particularly that having an up-up down-down topology. In particular, the active site is formed from one or more amino acids selected from one or more of the four helices forming the secondary stucture of the ob protein, especially a protein fragment consisting of amino acid residues 26 to 39, 74 to 88, 93 to 113 or 142 to 161. The compounds of the invention arc considered to be capable of regulating the physiological activity of the ob protein and are therefor of potential use in the treatment of nutritional and metabollic disorders, particularly obesity and diabetes in the case of agonists and anorexia and cachexia in the case of antagonists.

Abstract: Isolated DNA sequences encoding a novel hybrid protein are provided which comprise a portion of the CS protein of P. falciparum and the surface antigen of Hepatitis B virus. Vectors and host cells containing the isolated DNA sequences are also disclosed.

Abstract: A method for the treatment or prophylaxis of Syndrome X in a human or non-human mammal is disclosed. The method comprises the administration of an effective, non-toxic and pharmaceutically effective amount of an agonist of PPAR.alpha. and PPAR.gamma., or a pharmaceutically acceptable derivative thereof, to a human or non-human mammal in need thereof.

Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human .alpha..sub.v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.

Abstract: Monoclonal antibodies to the erythropoietin receptor are disclosed.

Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Abstract: A fusion protein comprising a portion of a glycoprotein of HCMV fused to a portion of a glycoprotein of HSV is described.

Abstract: A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher seroconversion and antibody titres than known commercial vaccines.

Abstract: Isolated nucleic acids encoding a human serine protease PSP1, protein obtainable from the nucleic acids, recombinant host cells transformed with the nucleic acids, oligonucleotides and primer pairs specific for PSP1 polymorphisms and use of the protein and nucleic acid sequences are disclosed.

Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.

Abstract: Methods and computer systems for identifying protein classes from nucleic acid or amino acid sequence data are disclosed.

Abstract: A novel hybrid protein is provided which comprises a portion of the CS protein of P. falciparum and the surface antigen of Hepatitis B virus. The use of this protein for vaccination purposes is disclosed.